

Substitute for form 1449A/PTO (Modified)		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/625,866
		Filing Date	July 22, 2003
		First Named Inventor	BROWN, Dennis M.
		Art Unit	1645 1614
		Examiner Name	To Be Assigned R. Henley
		Attorney Docket Number	A-72359/RFT/THR (468899-00037)
Sheet	1	of	1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<i>[Signature]</i>	A1	4,152,214	05-01-1979	Delfel et al.	
<i>[Signature]</i>	A2	6,630,173 B2	10-07-2003	Brown	
<i>[Signature]</i>	A3	6,734,178 B2	05-11-2004	Brown	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
<i>[Signature]</i>	B1	WO 95/29242	11-02-1995	The Children's Medical Center Corporation		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
<i>[Signature]</i>	C1	AUSPRUNK, D.H., et al., "Migration and Proliferation of Endothelial Cells in Preformed and Newly Formed Blood Vessels During Tumor Angiogenesis," <i>Microvasc. Res.</i> 14(1):53-65 (Jul. 1977).	
	C2	FIDLER, J., et al., "The implications of angiogenesis for the biology and therapy of cancer metastasis," <i>Cell</i> 79(2):185-188 (Oct. 1994).	
	C3	FOLKMAN, J., "How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A.," <i>Cancer Res.</i> 46(2):467-473 (Feb. 1986).	
	C4	FOLKMAN, J., "Tumor Angiogenesis," <i>Adv. Cancer Res.</i> 19:331-358 (1974).	
	C5	FOLKMAN, J., "What is the evidence that tumors are angiogenesis dependent?," <i>J. Natl. Cancer Inst.</i> 82(1):4-6 (Jan. 1990).	
	C6	GASPARINI, G., et al., "Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool," <i>J. Clin. Oncol.</i> 13(3):765-782 (Mar. 1995).	
	C7	O'REILLY, M., et al., "Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma," <i>Cell</i> 79(2):315-328 (Oct. 1994).	
	C8	POWELL, R.G., "Antitumor alkaloids for <i>Cephalotaxus harringtonia</i> : structure and activity," <i>J. Pharm. Sci.</i> 61(8):1227-1230 (Aug. 1972).	
	C9	STORGARD, C.M., et al., "Decreased Angiogenesis and Arthritic Disease in Rabbits Treated with an $\alpha v \beta 3$ Antagonist," <i>J. Clin. Invest.</i> 103(1):47-54 (Jan. 1999).	
	C10	WALSH, D.A., et al., "Angiogenesis in the Pathogenesis of Inflammatory Joint and Lung Diseases," <i>Arthritis Res.</i> 3(3):147-153 (Feb. 2001).	
	C11	WEIDNER, N., et al., "Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma," <i>New Eng. J. Med.</i> 324(1):1-8 (Jan. 1991).	
<i>[Signature]</i>	C12	WILKINSON-BERKA, J.L., et al., "The Interaction Between the Renin-Angiotensin System and Vascular Endothelial Growth Factor in the Pathogenesis of Retinal Neovascularization in Diabetes," <i>J. Vasc. Res.</i> 38(6):527-535 (Nov. - Dec. 2001).	

Examiner Signature	<i>[Signature]</i>	Date Considered	7/26/05
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2